

<i>Technology appraisal (TA)</i>	<i>Date of TA Release</i>	<i>Adherence of local formulary to NICE</i>	
		<i>Included on the Trust Formulary for this indication Yes OR No</i>	<i>Reason provided if "No"</i>
<b>2018-19</b>			
<a href="#">TA572 - Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes</a>	27/03/2019	<b>Yes</b>	
<a href="#">TA571 - Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib</a>	20/03/2019	<b>Yes</b>	
<a href="#">TA570 - Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)</a>	20/03/2019	<b>No</b>	Terminated appraisal
<a href="#">TA569 - Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer</a>	20/03/2019	<b>Yes</b>	
<a href="#">TA568 - Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)</a>	13/03/2019	<b>No</b>	Terminated appraisal
<a href="#">TA567 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies</a>	13/03/2019	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA566 - Cochlear implants for children and adults with severe to profound deafness</a>	07/03/2019	<b>No</b>	Not applicable - Medical device
<a href="#">TA565 - Benralizumab for treating severe eosinophilic asthma</a>	06/03/2019	<b>Yes</b>	
<a href="#">TA564 - Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)</a>	27/02/2019	<b>No</b>	Terminated appraisal
<a href="#">TA563 - Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer</a>	27/02/2019	<b>Yes</b>	
<a href="#">TA562 - Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma</a>	27/02/2019	<b>Yes</b>	
<a href="#">TA561 - Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia</a>	27/02/2019	<b>Yes</b>	
<a href="#">TA560 - Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)</a>	20/02/2019	<b>No</b>	Terminated appraisal
<a href="#">TA559 - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies</a>	23/01/2019	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA558 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease</a>	23/01/2019	<b>Yes</b>	
<a href="#">TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer</a>	10/01/2019	<b>Yes</b>	
<a href="#">TA556 - Darvadstrocel for treating complex perianal fistulas in Crohn's disease</a>	09/01/2019	<b>No</b>	Not recommended
<a href="#">TA555 - Regorafenib for previously treated advanced hepatocellular carcinoma</a>	09/01/2019	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA554 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years</a>	21/12/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA553 - Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence</a>	19/12/2018	<b>Yes</b>	
<a href="#">TA552 - Liposomal cytarabine—daunorubicin for untreated acute myeloid leukaemia</a>	19/12/2018	<b>Yes</b>	
<a href="#">TA551- Lenvatinib for untreated advanced hepatocellular carcinoma</a>	19/12/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA550 - Vandetanib for treating medullary thyroid cancer</a>	12/12/2018	<b>No</b>	Not recommended
<a href="#">TA549 - Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)</a>	05/12/2018	<b>No</b>	Terminated appraisal

<a href="#">TA548 - Decitabine for untreated acute myeloid leukaemia (terminated appraisal)</a>	05/12/2018	<b>No</b>	Terminated appraisal
<a href="#">TA547 - Tofacitinib for moderately to severely active ulcerative colitis</a>	28/11/2018	<b>Yes</b>	
<a href="#">TA546 - Padeliporfin for untreated localised prostate cancer</a>	21/11/2018	<b>No</b>	Not recommended
<a href="#">TA545 - Gemtuzumab ozogamicin for untreated acute myeloid leukaemia</a>	14/11/2018	<b>Yes</b>	
<a href="#">TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma</a>	17/10/2018	<b>Yes</b>	
<a href="#">TA543 - Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs</a>	03/10/2018	<b>Yes</b>	
<a href="#">TA542 - Cabozantinib for untreated advanced renal cell carcinoma</a>	03/10/2018	<b>Yes</b>	
<a href="#">TA541 - Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia</a>	19/09/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA540 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma</a>	03/09/2018	<b>Yes</b>	
<a href="#">TA539 - Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours</a>	29/08/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA538 - Dinutuximab beta for treating neuroblastoma</a>	22/08/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA537 - Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs</a>	08/08/2018	<b>Yes</b>	
<a href="#">TA536 - Alectinib for untreated ALK-positive advanced non-small-cell lung cancer</a>	08/08/2018	<b>Yes</b>	
<a href="#">TA535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine</a>	08/08/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA534 - Dupilumab for treating moderate to severe atopic dermatitis</a>	01/08/2018	<b>Yes</b>	
<a href="#">TA533 - Ocrelizumab for treating relapsing–remitting multiple sclerosis</a>	25/07/2018	<b>No</b>	Not applicable to CWFT - Specialist Centres only and CWFT is not a commissioning Centre
<a href="#">TA532 - Cenegeerin for treating neurotrophic keratitis</a>	18/07/2018	<b>No</b>	Not recommended
<a href="#">TA531 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer</a>	18/07/2018	<b>Yes</b>	
<a href="#">TA530 - Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy</a>	04/07/2018	<b>No</b>	Not recommended
<a href="#">TA529 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer</a>	04/07/2018	<b>Yes</b>	
<a href="#">TA528 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer</a>	04/07/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA527 - Beta interferons and glatiramer acetate for treating multiple sclerosis</a>	27/06/2018	<b>Yes</b>	
<a href="#">TA526 - Arsenic trioxide for treating acute promyelocytic leukaemia</a>	13/06/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</a>	13/06/2018	<b>Yes</b>	
<a href="#">TA524 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma</a>	13/06/2018	<b>Yes</b>	
<a href="#">TA523 - Midostaurin for untreated acute myeloid leukaemia</a>	13/06/2018	<b>No</b>	Not applicable to CWFT - Specialist Centres only and CWFT is not a commissioning Centre
<a href="#">TA522 - Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable</a>	13/06/2018	<b>Yes</b>	
<a href="#">TA521 - Guselkumab for treating moderate to severe plaque psoriasis</a>	13/06/2018	<b>Yes</b>	
<a href="#">TA520 - Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy</a>	16/05/2018	<b>Yes</b>	
<a href="#">TA519 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</a>	25/04/2018	<b>Yes</b>	
<a href="#">TA518 - Tocilizumab for treating giant cell arteritis</a>	18/04/2018	<b>No</b>	Not applicable to CWFT - Specialist Centres only and CWFT is not a commissioning Centre

<a href="#">TA517 - Avelumab for treating metastatic Merkel cell carcinoma</a>	11/04/2018	<b>Yes</b>	
--	------------	------------	--